Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus

Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr

Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity

Novel water-soluble analog of progesterone

Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation

Antibacterial agent

Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination

Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors.

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer

Antibiotic, inhibiting bacterial protein synthesis

Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo

Calcium channel blocker, blocking both T-type and L-type calcium channels

Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity

Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways

An impurity of Edoxaban, a novel inhibitor of factor Xa

Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders

Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle

Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria

Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme

Novel EBV activator, well-performing EBV lytic cycle inducer